We have rich experience in registration and declaration, and have completed the registration about more than 20 projects, among which more than 10 projects have been licensed for clinical trials. The T601 of Tasly Group which is the first approved oncolytic Vaccinia virus project in China.
We received nearly 20 on-site audit and assessment from domestic and foreign regulatory agencies and R&D enterprises, including provincial and municipal drug supervision departments, domestic CDC, Meria Group of France, Kyushu University of Japan, DNAVEC Company, Medifocus Inc, etc.
Integrated dedicated line
Address：3F, Building 2, Yinxing Zhijie Phase III, Xinlan Community, Guanlan Street, Longhua District, Shenzhen